Related Experiment Video
Updated: Aug 13, 2025
Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss
Published on: July 19, 2024
CX08005, a Protein Tyrosine Phosphatase 1B Inhibitor, Attenuated Hepatic Lipid Accumulation and Microcirculation
Jiang Li1,2, Xiaolin Zhang1,2, Jinying Tian1,2
1Beijing Key Laboratory of New Drug Mechanisms and Pharmacological Evaluation Study, Institute of Materia Medica, Chinese Academy of Medical Science & Peking Union Medical College, 1 Xiannongtan St., Beijing 100050, China.
Abstract:
Nonalcoholic fatty liver disease (NAFLD) is one of the common metabolic diseases characterized by hepatic lipid accumulation. Insulin resistance and microcirculation dysfunction are strongly associated with NAFLD. CX08005, an inhibitor of PTP1B with the IC50 of 0.75 ± 0.07 μM, has been proven to directly enhance insulin sensitivity. The present study aimed to investigate the effects of CX08005 on hepatic lipid accumulation and microcirculation dysfunction in both KKAy mice and diet-induced obesity (DIO) mice. Hepatic lipid accumulation was evaluated by hepatic triglyceride determination and B-ultrasound analysis in KKAy mice. Insulin sensitivity and blood lipids were assessed by insulin tolerance test (ITT) and triglyceride (TG)/total cholesterol (TC) contents, respectively. In addition, the hepatic microcirculation was examined in DIO mice by in vivo microscopy. The results showed that CX08005 intervention significantly reduced the TG and echo-intensity attenuation coefficient in the livers of KKAy mice. Furthermore, we found that CX08005 treatment significantly enhanced insulin sensitivity, and decreased plasma TG and/or TC contents in KKAy and DIO mice, respectively. In addition, CX08005 treatment ameliorated hepatic microcirculation dysfunction in DIO mice, as evidenced by increased RBCs velocity and shear rate of the blood flow in central veins and in the interlobular veins, as well as enhanced rate of perfused hepatic sinusoids in central vein area. Additionally, CX08005 administration decreased the adhered leukocytes both in the center veins and in the hepatic sinusoids area. Taken together, CX08005 exhibited beneficial effects on hepatic lipid accumulation and microcirculation dysfunction associated with NAFLD, which was involved with modulating insulin sensitivity and leukocyte recruitment, as well as restoration of normal microcirculatory blood flow.
Insights
CX08005, a PTP1B inhibitor, improves nonalcoholic fatty liver disease (NAFLD) by reducing liver fat and enhancing insulin sensitivity. It also improves liver microcirculation and reduces inflammation in mouse models.
Area of Science:
- Metabolic disease research
- Pharmacology
- Hepatology
Background:
- Nonalcoholic fatty liver disease (NAFLD) involves hepatic lipid accumulation, insulin resistance, and microcirculation dysfunction.
- PTP1B inhibition is a potential therapeutic strategy for metabolic disorders.
Purpose of the Study:
- To investigate the effects of CX08005, a PTP1B inhibitor, on hepatic lipid accumulation and microcirculation dysfunction in NAFLD mouse models.
- To assess CX08005's impact on insulin sensitivity and blood lipid profiles.
Main Methods:
- CX08005 efficacy was tested in KKAy and diet-induced obesity (DIO) mice.
- Hepatic lipid accumulation assessed via triglyceride levels and B-ultrasound.
- Insulin sensitivity evaluated using insulin tolerance tests (ITT).
- Hepatic microcirculation examined using in vivo microscopy.
Main Results:
- CX08005 significantly reduced liver triglycerides and improved ultrasound indicators in KKAy mice.
- Improved insulin sensitivity and decreased plasma triglyceride/cholesterol observed in both models.
- Enhanced hepatic microcirculation, including increased red blood cell velocity and perfusion.
- Reduced leukocyte adhesion in liver vasculature.
Conclusions:
- CX08005 demonstrates therapeutic potential for NAFLD by improving lipid metabolism and insulin sensitivity.
- CX08005 ameliorates hepatic microcirculation dysfunction and reduces inflammation.
- The drug's benefits are linked to modulating insulin sensitivity, leukocyte recruitment, and blood flow restoration.
